NasdaqGS - Delayed Quote USD
Passage Bio, Inc. (PASG)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 7:38 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
76,718.0000
102,999.0000
135,394.0000
177,729.0000
111,902.0000
--
Operating Income
-76,718.0000
-102,999.0000
-135,394.0000
-177,729.0000
-111,902.0000
--
Net Non Operating Interest Income Expense
--
--
2,269.0000
343.0000
670.0000
696.0000
Other Income Expense
148.0000
937.0000
-731.0000
-8,000.0000
-1,000.0000
--
Pretax Income
-76,570.0000
-102,062.0000
-136,125.0000
-185,386.0000
-112,232.0000
--
Net Income Common Stockholders
-76,570.0000
-102,062.0000
-136,125.0000
-185,386.0000
-112,232.0000
--
Diluted NI Available to Com Stockholders
-76,570.0000
-102,062.0000
-136,125.0000
-185,386.0000
-112,232.0000
--
Basic EPS
-1.35
-1.86
-2.50
-3.48
-2.46
--
Diluted EPS
-1.35
-1.86
-2.50
-3.48
-2.46
--
Basic Average Shares
56,912.2500
54,743.4900
54,429.0230
53,343.9590
45,614.8070
--
Diluted Average Shares
56,912.2500
54,743.4900
54,429.0230
53,343.9590
45,614.8070
--
Total Operating Income as Reported
-82,546.0000
-108,389.0000
-138,394.0000
-185,729.0000
-112,902.0000
--
Total Expenses
76,718.0000
102,999.0000
135,394.0000
177,729.0000
111,902.0000
--
Net Income from Continuing & Discontinued Operation
-76,570.0000
-102,062.0000
-136,125.0000
-185,386.0000
-112,232.0000
--
Normalized Income
-70,742.0000
-96,672.0000
-133,125.0000
-177,386.0000
-111,232.0000
--
Interest Income
--
--
2,269.0000
343.0000
670.0000
696.0000
Net Interest Income
--
--
2,269.0000
343.0000
670.0000
696.0000
EBIT
-76,718.0000
-102,999.0000
-135,394.0000
-177,729.0000
-111,902.0000
--
EBITDA
-73,350.0000
-99,278.0000
-131,715.0000
-176,186.0000
-111,102.0000
--
Reconciled Depreciation
3,368.0000
3,721.0000
3,679.0000
1,543.0000
800.0000
--
Net Income from Continuing Operation Net Minority Interest
-76,570.0000
-102,062.0000
-136,125.0000
-185,386.0000
-112,232.0000
--
Total Unusual Items Excluding Goodwill
-5,828.0000
-5,390.0000
-3,000.0000
-8,000.0000
-1,000.0000
--
Total Unusual Items
-5,828.0000
-5,390.0000
-3,000.0000
-8,000.0000
-1,000.0000
--
Normalized EBITDA
-67,522.0000
-93,888.0000
-128,715.0000
-168,186.0000
-110,102.0000
--
12/31/2019 - 2/28/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
STOK Stoke Therapeutics, Inc.
13.00
-2.03%
NXTC NextCure, Inc.
1.3700
-5.52%
ORIC ORIC Pharmaceuticals, Inc.
9.45
+3.28%
PLRX Pliant Therapeutics, Inc.
15.20
+3.61%
CABA Cabaletta Bio, Inc.
4.9050
+1.13%
BDTX Black Diamond Therapeutics, Inc.
3.3100
+2.80%
SNSE Sensei Biotherapeutics, Inc.
0.4131
-5.25%
CMRX Chimerix, Inc.
0.8810
+1.00%
PMVP PMV Pharmaceuticals, Inc.
1.5800
-1.25%
DTIL Precision BioSciences, Inc.
8.94
-0.22%